GlassScriptPhysician profile
Jennifer A Camas
NPI 1902828114
$5,822.97
in general payments reported to CMS, 2019-2025
39 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.20 · 2020: $321 · 2021: $936 · 2022: $1,373 · 2023: $1,087 · 2024: $1,040 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123 · Education: $22.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.18 |
| Education | $22.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,463.43 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $830.51 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $596.09 | 2021-2025 | |
| Axsome Therapeutics, INC. | $387.53 | 2022-2025 | Auvelity |
| Novo Nordisk INC | $343.53 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $265.45 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Corcept Therapeutics | $242.45 | 2024-2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $167.51 | 2022 | |
| Lundbeck LLC | $162.46 | 2021-2025 | Vyepti, Rexulti |
| Regeneron Healthcare Solutions, INC. | $145.74 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $130.55 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $104.70 | 2023-2025 | |
| Glaxosmithkline, LLC. | $97.08 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $91.13 | 2020-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $73.93 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Camas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.